Splice-modulation therapy, whereby molecular manipulation of premessenger RNA splicing is engineered to yield genetic correction, is a promising novel therapy for genetic diseases of muscle and nerve-the prototypical example being Duchenne muscular dystrophy. Duchenne muscular dystrophy is the most common childhood genetic disease, affecting one in 3500 newborn boys, causing progressive muscle weakness, heart and respiratory failure and premature death. No cure exists for this disease and a number of promising new molecular therapies are being intensively studied. Duchenne muscular dystrophy arises due to mutations that disrupt the open-reading-frame in the DMD gene leading to the absence of the essential muscle protein dystrophin. Of all novel molecular interventions currently being investigated for Duchenne muscular dystrophy, perhaps the most promising method aiming to restore dystrophin expression to diseased cells is known as 'exon skipping' or splice-modulation, whereby antisense oligonucleotides eliminate the deleterious effects of DMD mutations by modulating dystrophin pre-messenger RNA splicing, such that functional dystrophin protein is produced. Recently this method was shown to be promising and safe in clinical trials both in The Netherlands and the UK. These trials studied direct antisense oligonucleotide injections into single peripheral lower limb muscles, whereas a viable therapy will need antisense oligonucleotides to be delivered systemically to all muscles, most critically to the heart, and ultimately to all other affected tissues including brain. There has also been considerable progress in understanding how such splice-correction methods could be applied to the treatment of related neuromuscular diseases, including spinal muscular atrophy and myotonic dystrophy, where defects of splicing or alternative splicing are closely related to the disease mechanism.
Introduction excision-known as pre-mRNA splicing-to yield a mature mRNA that, after editing, will include coding elements and signals appropriate for translation into functional protein (Crick, 1979) . The natural complexity of pre-mRNA splicing also allows the exclusion (or inclusion) of specific exons by a process known as alternative splicing (Matlin et al., 2005) . While there is a surprisingly small amount of diversity in genome size between organisms of widely differing complexity, the importance of alternative splicing lies in its contribution to the generation of proteomic diversity. In an extreme example of the amplification of proteomic diversity possible through alternative splicing, the Drosophila 'Dscam' gene, which encodes a cell surface axon guidance protein, generates as many as 38 016 alternatively spliced isoforms (Schmucker and Flanagan, 2004) . Moreover, alternative splicing is now known to be the norm rather than the exception within the human genome, with up to 70% of genes generating alternatively spliced products (Modrek and Lee, 2002; Hertel, 2008) . The control of alternative splicing events involving the definition of exon/intron boundaries through spliceosome and small nuclear RNA (snRNA) recognition of pre-mRNA signatures is complex but critical for cell function (Fig. 1) . Perhaps unsurprisingly, alternative splicing is known to be especially prominent in the mammalian nervous system, where the resulting rich proteomic diversity reflects the complexity of cellular processes and interactions (Blencowe, 2006) . Recently, through the development of increasingly powerful genome-wide mapping methods it is now possible to reveal specific splicing factor (protein)-RNA interaction maps across whole brain (Licatalosi et al., 2008) . Taken together, it is therefore not unexpected that an increasing number of neurological and neuromuscular disorders are being discovered to have direct or indirect links to defects in constitutive or alternative splicing (Table 1) ; perhaps the best characterized examples being Duchenne muscular dystrophy Splicing is initiated by recognition of the 5' splice site (GU) by the U1 snRNP (small nuclear ribonucleoprotein) and 3' splice site including the branch point, polypyrimidine tract and AG by the U2 snRNP/U2AF splicing factor complex. Upon binding of the other splicing factors, a lariat is formed between a 5' splice site and a branch point. A rearrangement then occurs that removes the lariat and ligates the exons together. The presence of splice enhancers and silencers, which affect the recognition of the splice sites by the respective factors, can result in a number of alternatively spliced variants arising from a single pre-mRNA transcript, generating a range of different protein isoforms. Four examples of this are shown (arrowed numbers 1-4 in the left, middle-left, middle-right and right hand panels), including: alternate inclusion of exons within the final mature mRNA transcript (1 versus 2); usage of different 5' and 3' splice sites leading to alternate exon usage (2 versus 3) and exclusion of exons (4). These and other modes of pre-mRNA usage can result in alternate transcription start sites, coding region usage, stop codon introduction and different 5' and 3' untranslated regions, all of which can contribute to mature mRNA and thus proteomic diversity. Licatalosi et al., 2008; Lagier-Tourenne and Cleveland, 2009; Zhang et al., 2009 Ataxia telangiectasia
Mutations within the ATM gene Activation of cryptic splice sites and affects on RNA structure causing defective ATM pre-mRNA splicing Teraoka et al., 1999; Pagani et al., 2002; Buratti et al., 2007 Fragile X and Fragile X-associated tremor/ataxia syndrome CGG repeat expansions in FMR1 gene
Gain-of-function RNA effect via sequestration of RNA-splicing factors Jin et al., 2003; Ranum and Cooper, 2006 Frontotemporal dementia and parkinsonism linked to chromosome 17 MAPT gene mutations affecting splicing enhancers or silencers Altered alternative splicing of microtubule-associated protein tau exon 10 D 'Souza et al., 1999; Grover et al., 1999; Andreadis, 2005 DMD and BMD
DMD gene deletions and mutations
DMD gene loss-of-function with infrequent splicing defects leading to phenotypic heterogeneity Ahn and Kunkel, 1993; Muntoni et al., 2003 Non-syndromic hearing loss 
DMD and splice-modulation therapy
DMD and its milder allelic variant Becker muscular dystrophy (BMD) are X-linked disorders that arise from mutations, typically large deletions, in the DMD gene-the largest gene in the human genome . In the case of DMD, deletions (65%), but also duplications, point mutations or other smaller gene rearrangements affect alternative pre-mRNA splicing to generate an out-of-frame DMD transcript, leading to aberrant pre-mRNA translation and consequently an absence of the essential muscle protein dystrophin. Dystrophin, first characterized in 1987 (Hoffman et al., 1987) , is an integral molecular constituent of the dystrophin-glycoprotein complex, a large multi-component membrane complex that provides a mechanical and signalling link between the actin cytoskeleton in muscle and the extracellular matrix (Davies and Nowak, 2006) . The absence of dystrophin renders muscle cells susceptible to stretch-induced damage, increased intracellular calcium influx, and is followed by muscle fibre degeneration. Patients with DMD suffer from severe, progressive muscle wasting leading to loss of ambulation and respiratory weakness. Cardiac involvement is found in up to 90% of DMD patients and a large number of patients develop dilated cardiomyopathy leading to cardiac death (Bushby et al., 2003) . In contrast, BMD arises from mutations/deletions in which the DMD pre-mRNA transcript is maintained in-frame. As a result, pre-mRNA processing yields a truncated dystrophin protein lacking domains corresponding to the exonic sequences affected by the mutation. Thus, BMD is in general much less severe a disorder than DMD, given that dystrophin protein is present, but there is considerable heterogeneity due to the fact that different mutations result in the elimination of distinct functional domains within the resulting dystrophin protein (Aartsma-Rus et al., 2006a)-some more critical and essential for function than others. While glucocorticosteroid therapy is currently the gold standard treatment for DMD, bringing about a modest increase in life expectancy (Bushby et al., 2004) , the most promising treatment strategies for DMD aim to restore expression of dystrophin protein, thus targeting the primary defect. Several promising new therapeutic methods currently exist (van Deutekom and van Ommen, 2003) . These include gene replacement therapy using adeno-associated virus transduction. This approach presents major challenges including the very high viral titres required for systemic gene delivery, the size and complexity of the DMD gene which currently precludes its packaging as an entire functional unit within the adeno-associated virus genome, and immunological concerns. Nevertheless gene therapy is in early stage clinical trials in the USA. A second method relates to up-regulation of the closely related gene homologue utrophin, which has been shown experimentally to compensate for the loss of dystrophin function (Tinsley et al., 1996) . Progress has been made to identify small molecules capable of up-regulating utrophin expression (Hirst et al., 2005) and it is anticipated that a lead compound will enter clinical trials in 2010. A third therapeutic approach applicable to point mutations in the DMD gene that introduce premature termination codons (510% of all DMD patients), is afforded by drugs that permit translational read-through of such mutations. The prototype in this class is the small molecule drug PTC124 (Ataluren Õ ), identified by high-throughput screening, which has shown encouraging safety and tolerability in Phase I and IIa clinical studies (Welch et al., 2007) . Perhaps most promising of all novel molecular interventions for DMD at present is dystrophin splice-modulation, whereby short antisense oligonucleotides are utilized to manipulate processing of the DMD pre-mRNA to restore the DMD open reading frame and yield the production of de novo functional dystrophin protein (Aartsma-Rus and van Ommen, 2007) .
Molecular basis of antisense oligonucleotide splice-modulation for DMD
The theoretical basis for the development of splice-modulation therapies for DMD is threefold. First, the idea that antisense oligonucleotides could be directed to modulate splicing of pre-mRNA transcripts arose from seminal observations on the b-globin gene associated with b-thalassaemia (Dominski and Kole, 1993) . Secondly, the existence of so-called revertant fibres, individual dystrophin-positive fibres, found in at least 50% of all DMD patients, indicated the presence of an intrinsic alternative splicing mechanism that could, albeit erratically and at low efficiency, successfully restore dystrophin protein expression within individual myocytes (Lu et al., 2000) . Finally, the internally shortened dystrophin proteins characteristically found in BMD patients are capable of function, since they contain the critical carboxy-and amino-terminal domains of the protein, as demonstrated in several BMD families with in-frame deletions of, for example, exons 32-44, 48-51 or 48-53 (Melis et al., 1998) , and which as a result display no clinical myopathy. This theoretical foundation has led to the investigation of methods for splicing modulation of the DMD gene over the last decade. Typically, effective antisense oligonucleotide-mediated splice-modulation of the DMD pre-mRNA requires the elimination via exon skipping of specific DMD exons and their flanking regions to yield an in-frame but internally truncated transcript capable of producing functional dystrophin protein (Fig. 2) . Effective exon skipping antisense oligonucleotides are short, typically 20-30 nucleotides in length, and homologous in sequence to regions of the pre-mRNA transcript at or in close proximity to the relevant DMD exon targeted for skipping. Such target sequences most commonly correspond to motifs or other sites within the target exon (e.g. exonic splicing enhancer or other sites) (Aartsma-Rus et al., 2005 , 2009b Wilton et al., 2007) but may also target neighbouring intron/exon boundaries (splice donor or splice acceptor sites), or branch point sequences within the neighbouring introns. The earliest evidence for successful exon skipping of the DMD gene and restoration of dystrophin protein was obtained in vitro in human lymphoblastoid and mdx mouse muscle cells (Takeshima et al., 1995; Pramono et al., 1996; Dunckley et al., 1998) . Subsequently, numerous in vitro exon skipping studies have been undertaken including demonstration of precise skipping of dmd exon 23 in mdx mouse muscle cells (Wilton et al., 1999) Convincing pre-clinical evidence for the therapeutic potential of exon skipping for DMD has come from numerous in vivo studies in animal models of the disease, most notably the mdx mouse, but also in humanized DMD mice (Bremmer-Bout et al., 2004; Heemskerk et al., 2009 ) and canine models of muscular dystrophy (McClorey et al., 2006; Yokota et al., 2009) . The mdx mouse is a dystrophin-deficient mutant that arises from the effects of a single nucleotide base substitution and introduction of a premature termination codon in exon 23 of the DMD gene (Bulfield et al., 1984; Sicinski et al., 1989) . The phenotype of this mouse is relatively mild with a close to normal lifespan, but it has nevertheless proved an excellent model in which to demonstrate and fine-tune methods for molecular correction of the dystrophin defect. Evidence for in vivo correction of the dystrophin protein defect by antisense oligonucleotide-mediated exon skipping was first shown in mdx mice in 2001 (Mann et al., 2001 ) and this led to subsequent In DMD patients bearing for example a nonsense point-mutation in exon 51, skipping of more than one exon will be required to establish an in-frame DMD transcript. By skipping both exons 50 and 51, in this case using a cocktail of antisense oligonucleotides directed to these exonic regions, a shortened but again partly functional dystrophin protein can be produced. (D) Limitations to the exon skipping approach for DMD. Antisense oligonucleotide-mediated exon skipping will not be applicable when the mutations directly disrupt critical functional dystrophin protein domains (e.g. exon 66 in the distal cysteine-rich domain), since effective splice-modulation of these pre-mRNA defects will not yield functional protein. DAPC = dystrophin associated protein complex.
experiments in which restoration of dystrophin protein expression and function was observed (Lu et al., 2003) . In these experiments, Partridge, Wilton and colleagues injected 2 0 OMe modified antisense oligonucleotides (RNA analogues incorporating methyl modifications at the 2 0 ribose position), the sequences of which were complementary to the mouse DMD exon/intron 23 boundary region, into the tibialis anterior muscles of adult mdx mice. These authors were able to detect corrected DMD pre-mRNA transcripts lacking the mutated exon 23 (i.e. successful exon 23 skipping) and demonstrated restored dystrophin protein expression with the correct sarcolemmal cellular localization required for physiological function. Moreover, this indeed led to restored dystrophin function both in terms of reconstituted molecular expression of dystrophin-glycoprotein complex protein components (demonstrating that the restored dystrophin protein contained the requisite functional domains for essential protein-protein interactions) and improved isometric force generation in treated muscles. Two limitations to antisense oligonucleotide-mediated splicemodulation were clear at the time of this work in 2003. First, despite phosphorothioate modification, the 2 0 OMe antisense oligonucleotides required co-administration with a co-polymer (F127) to facilitate cell uptake following intramuscular injection, suggesting that in vivo delivery of antisense oligonucleotides would be challenging. Secondly, the level of restored dystrophin protein was low. These data were confirmed by other groups, and as a consequence one important area in which subsequent research effort was focused has been to develop antisense oligonucleotides with improved exon skipping efficiency, principally through the investigation of new generations of antisense oligonucleotides with enhanced chemical properties. Morpholino phosphorodiamidate (PMO) antisense oligonucleotides have a stable, uncharged backbone, in contrast to the negatively charged 2 0 OMe phosphorothioate compounds, and were shown initially to induce mdx DMD exon 23 skipping successfully both in vitro (Gebski et al., 2003) and in vivo . A second uncharged antisense oligonucleotide compound, peptide nucleic acid, was also shown to have good exon skipping activity in mdx mice (Ivanova et al., 2008a, b; Yin et al., 2008a) . As a result, there now exist several antisense oligonucleotide candidates with distinct backbone chemical properties for clinical trials. An alternative approach entirely to the use of short synthetic antisense oligonucleotides has been to encode appropriate exon skipping antisense sequences within DNA expression vectors, offering the prospect both of improved delivery (since such approaches can make use of viral vector delivery methods) and duration of effect, and also improved skipping efficiency. In the first in vivo report of this work, Goyenvalle and colleagues (2004) were able to demonstrate persistent DMD exon 23 skipping in mdx mice by expression of antisense sequences linked to a U7 snRNA in an adeno-associated virus vector (Goyenvalle et al., 2004) . This approach arose from earlier in vitro work using U1 snRNA backbones (De Angelis et al., 2002) , the natural function of which involves recognition of 5 0 splice junctions in pre-mRNAs-hence their powerful utility for such applications, and which have subsequently shown evidence of good systemic activity and phenotypic improvement in mdx mice (Denti et al., 2006) . Lu et al. (2003) and a 20-mer sequence (PRO051) designed to skip human exon 51 was injected unilaterally into the tibialis anterior muscles of four patients with DMD. The results of this trial proved encouraging, with the treatment being well tolerated and up to 35% dystrophin-positive fibres detected in biopsy samples from all treated patients (van Deutekom et al., 2007) . On the basis of developments in antisense oligonucleotide backbone chemistry following 2003 (Gebski et al., 2003; Fletcher et al., 2006 Fletcher et al., , 2007 , the UK team selected a PMO antisense oligonucleotide (working in collaboration with AVI Biopharma) for their clinical trial and conducted an extensive screen of antisense oligonucleotide sequences to maximize exon skipping efficiency, before selecting the most efficacious 30-mer sequence targeting exon 51 (Arechavala-Gomeza et al., 2007) . In this clinical trial, a single administration of PMO antisense oligonucleotide (AVI-4658) was injected unilaterally into the extensor digitorum brevis muscles of seven patients, in a single-blind, dose-escalation protocol that included a placebo control administered to the contralateral extensor digitorum brevis muscle. This study too was highly encouraging. PMO antisense oligonucleotides were also well tolerated by all patients, and at the higher dose received by five of the seven patients, de novo dystrophin protein expressed at up to 42% of normal levels in dystrophin-positive fibres (Kinali et al., 2009 Results from these clinical trials will inform future research, but given the encouraging data already obtained, it is clear that future research must now focus on the critical scientific and other barriers that currently limit successful clinical application of antisense oligonucleotide splice-modulation therapy for DMD. In investigations of all novel RNA-based therapies, including RNA interference-based therapies as well as antisense oligonucleotide therapies, in vivo delivery of the therapeutic compounds represents the single greatest obstacle to successful clinical exploitation. In the case of DMD, there are two pertinent issues. First, the nature of the disease process itself involving muscle degeneration leads to disturbed sarcolemmal integrity and hence a reduced barrier to antisense oligonucleotide delivery into muscle that works in favour of effective antisense oligonucleotide delivery in this specific case (Hoffman, 2007) . However, second, given that it is a systemic disease affecting all peripheral skeletal muscles, including diaphragm, smooth and cardiac muscle and also the brain, development of a successful splice-modulation therapy is critically dependent on effective antisense oligonucleotide delivery to and splice-modulation in all affected tissues. Systemic intravenous delivery of both 2 0 OMe and PMO antisense oligonucleotides has been shown to restore dystrophin protein expression in the dystrophin-deficient mdx mice (Lu et al., 2005; Alter et al., 2006) . However, in these experiments, high dose (up to 100 mg/kg), multi-injection antisense oligonucleotide administration was required to generate detectable dystrophin protein expression in multiple peripheral muscle groups. Even at such doses the correction efficiency remained relatively low for both antisense oligonucleotide chemistries, up to 16 and 25% dystrophin-positive fibres with 2 0 OMe and PMO antisense oligonucleotides, respectively, following three injections (Lu et al., 2005; Alter et al., 2006) , with focal and highly variable levels of protein restored in different muscle groups. These findings suggested that at best antisense oligonucleotide splice-correction therapy may have only partial clinical efficacy in DMD patients, unless higher equivalent doses can be used in human subjects or improved antisense oligonucleotide delivery and/or administration regimens are developed. A second related scientific barrier to successful clinical application is that in neither of these high dose antisense oligonucleotide studies was dystrophin protein shown to be restored in mdx heart muscle. This is an important consideration given that cardiac problems are found in nearly all (up to 90%) patients with DMD patients, a significant number of whom develop a dilated form of cardiomyopathy leading to cardiac death (Bushby et al., 2003) . Moreover, there are concerns that a method for the effective correction of the skeletal muscle dystrophin defect, in the absence of cardiac correction, might worsen cardiac disease progression in DMD (Townsend et al., 2008) . Thus the development in parallel of methods to correct the cardiac DMD phenotype is of great importance. Novel methods for improved systemic antisense oligonucleotide delivery have thus been intensively investigated with the aim of permitting lower antisense oligonucleotide doses to be used, compatible with acceptable safety and toxicity profiles, and to facilitate more effective systemic antisense oligonucleotide delivery to all DMD-affected tissues, ideally targeted specifically to such tissues. Recently a number of groups have independently reported that the systemic intravenous delivery of uncharged PMO antisense oligonucleotides can be enhanced significantly by direct PMO conjugation to short, arginine-rich, cell-penetrating peptides (Jearawiriyapaisarn et al., 2008; Wu et al., 2008 Wu et al., , 2009 Yin et al., 2008b) . Cell-penetrating peptides are short peptides (mostly cationic) that were found to impart cell-penetrating properties to attached cargoes. They were initially identified as sections of proteins (protein transduction domains), for example the argininerich nuclear localization signal of the HIV-1 trans-activator of transcription protein Tat (Vives et al., 1997 ) and the well-described helix 3 peptide of the Drosophila 'Antennapedia' gene transcriptional activator (which became known as Penetratin) (Derossi et al., 1994) . Later, synthetic variants of such cell-penetrating peptides were developed, of which the most effective in the case of PMO and peptide nucleic acid were a peptide family the parent of which is known as 'R', a 14-mer that contains four contiguous Arg-Aminohexanoyl-Arg (R-X-R) motifs (Nelson et al., 2005) . Pharmacologically, R-PMO has shown a 2-fold increase in elimination half-life, 4-fold increase in volume of distribution, and better tissue uptake when injected into rats compared to unconjugated PMO (Nelson et al., 2005) . More recently another family of arginine-rich peptide derivatives based on Penetratin extended by six Arg residues (R6Pen) (Abes et al., 2007) and their serum-stabilized versions (Pip) have been advanced (Ivanova et al., 2008a, b) . Commercially, the leading peptide at present is known as 'B': a 14-mer peptide variant of 'R' with sequence (R-X-R-R-B-R) 2 -X-B, where 'B' is b-Alanyl, which is thought to have a favourable toxicology profile (Stein et al., 2008) .
In all of the R-PMO and B-PMO studies to date, highly significant body-wide dystrophin protein restoration in multiple peripheral muscle groups at low PMO doses has been reported, with some limited correction in cardiac muscle seen for the first time, and with convincing amelioration of the mdx mouse dystrophic phenotype (Jearawiriyapaisarn et al., 2008; Wu et al., 2008 Wu et al., , 2009 Yin et al., 2008b) . These studies have therefore highlighted the potential of peptide-PMO antisense oligonucleotide conjugates as novel and powerful therapeutic agents for DMD. B-PMO (also known simply as PPMO) is the lead PMO candidate compound for DMD being developed by AVI Biopharma, the first clinical trial of which is likely to take place in the USA targeting DMD exon 50. However, these early studies have yet to explore the full range of peptide design space, and in particular have not yet investigated methods for specific peptide targeting of muscle and heart and other affected tissues. Recently, the first report of such muscle-targeted antisense oligonucleotide delivery demonstrated that chimeric peptides incorporating muscle-specific heptapeptide and cell-penetrating peptide domains (prototype B-MSP-PMO) could indeed yield targeted antisense oligonucleotide delivery and improved dystrophin splice correction in mdx mice (Yin et al., 2009) . Thus PPMO drugs have considerable potential as therapeutic agents but given their novelty, extensive safety testing of these compounds will be required before first-in-man studies can proceed. Finally, while at an early stage, recent developments in nanotechnology look promising for providing antisense oligonucleotide delivery for DMD. In one study, nanoparticles were successfully engineered to deliver antisense oligonucleotides for exon skipping via intramuscular injection in mdx mice (Sirsi et al., 2009) and in another, cationic nanoparticles incorporating a low dose of 2 0 OMePS antisense oligonucleotides were delivered via the intraperitoneal route to mdx mice and showed evidence of systemic activity and low level dystrophin restoration (Rimessi et al., 2009 ).
Dystrophin correction in heart and other affected tissues
As successful methods are developed to enhance the systemic delivery and activity of antisense oligonucleotides for DMD therapy, the question of efficacy in affected non-muscle tissues, especially heart, will become increasingly important. DMD is a systemic disease, and cardiomyopathy is the second leading cause for the death in patients with DMD, accounting for 10-40% of fatalities in DMD populations (Cox and Kunkel, 1997; Muntoni et al., 2003) . Even female carriers are reported to have a higher risk of developing cardiomyopathy (Politano et al., 1996; Saito et al., 1996) . There is increasing emphasis on early cardiac intervention in DMD patients with medical treatments including angiotensin-converting enzyme inhibitors alone, or in combination with beta-blockers and glucocorticosteroid therapy (Markham et al., 2008; Ogata et al., 2009) . However, there are currently a lack of good efficacy data for long-term use of these treatments in patients with DMD (Finsterer, 2009; Ogata et al., 2009) . Ultimately there is a clear need for new molecular therapies to correct the cardiac dystrophin defect as well. In the case of exon skipping, the degree to which cardiac correction can be achieved and disease progression delayed will depend on the efficiency of antisense oligonucleotide delivery to the heart, the degree of dystrophin splice-modulation achieved, and crucially, to what extent the dystrophin isoform successfully generated has functional utility in heart. In this regard it should be noted that there is wide heterogeneity in the BMD cardiac phenotype, but that in general such patients typically have a higher incidence of cardiac disease although often this is subclinical and late onset (Finsterer and Stollberger, 2003) . Despite very high antisense oligonucleotide doses, systemically administered 2 0 OMe and PMO antisense oligonucleotides failed to demonstrate evidence of splice-modulation in mdx mouse heart (Lu et al., 2005; Alter et al., 2006) . A more recent study, utilizing even higher doses (nine doses at 100 mg/kg), reported very low levels (1-2%) of dystrophin splice-modulation in heart with both antisense oligonucleotide chemistries (Heemskerk et al., 2009) . The reasons for the low efficiency cardiac dystrophin splice-modulation are unclear, but are probably related to the poor ability of unmodified antisense oligonucleotides to traverse the endothelial barrier in heart microvasculature and/or enter cardiomyocytes with sufficient efficacy to yield detectable dystrophin correction. However, more recent work from several laboratories with PMO compounds has shown evidence of significantly restored cardiac dystrophin protein for the first time, albeit at low levels compared with skeletal muscle (Jearawiriyapaisarn et al., 2008; Wu et al., 2008 Wu et al., , 2009 Yin et al., 2008b) . This is encouraging and important since it demonstrates that there is no intrinsic barrier within cardiomyocytes preventing effective dystrophin exon skipping and suggests that a solution to cardiac antisense oligonucleotide delivery can be found. Nevertheless, the precise function of cardiac dystrophin and the level of restored dystrophin that would be required for cardiac correction and disease modification in DMD patients remain unclear. There are fundamental structural differences between cardiac and skeletal muscles with respect to dystrophin, e.g. dystrophin expression pattern and the localization of dystrophin within T-tubules in cardiac but not skeletal muscle (Porter et al., 1992; Klietsch et al., 1993; Kaprielian et al., 2000; Rybakova et al., 2000; Yasuda et al., 2005; Duan, 2006) , all of which might contribute to different functional requirements for dystrophin in heart and to variation in the efficacy of antisense oligonucleotide activity in these two types of muscle. Recently, in unpublished work, we have demonstrated the striking potential of Pip series cell-penetrating peptides (Ivanova et al., 2008a, b) to restore cardiac dystrophin protein when attached to PMO. In particular, the activity of a new peptide Pip5e has resulted in almost complete cardiac dystrophin restoration in mdx mice following intravenous delivery (Wood, Gait and Yin, unpublished data) . This was unexpected and at present the mechanism is not known since the central ILFQY domain with Pip5e is not known to be a heart-specific sequence. Nevertheless such data point towards future research needed to optimize antisense oligonucleotide therapy for DMD fully. Such discoveries are also likely to be of direct relevance to the development of biological therapies for other neuromuscular and cardiac disorders which face similar delivery challenges. Brain and retina are two other major non-muscle sites of dystrophin expression. Full-length dystrophin (Dp427) and other isoforms (Dp140 and Dp71) are expressed in cerebral cortex, cerebellum, hippocampus and Purkinje cells (Lidov et al., 1990) . About 30% of DMD patients show non-progressive intellectual and/or cognitive impairment (Bresolin et al., 1994; Wicksell et al., 2004) and a sub-set show an increased incidence of psychiatric disorders; e.g. autism, dysthymic and depressive disorders (Komoto et al., 1984; Fitzpatrick et al., 1986; Ogata et al., 2009) . Interestingly, a recent study has suggested that dystrophin loss influences emotionally defensive behaviour in mdx mice and that this behavioural change can be ameliorated by the restoration of dystrophin induced by direct intracerebroventricular PMO antisense oligonucleotide treatment (Sekiguchi et al., 2009) . However the role of dystrophin in brain is not fully understood. In retina, three different dystrophin isoforms exist; Dp427, Dp71 and Dp260-the latter being the dominant form. Dp427 is mainly expressed at the photoreceptor terminal and its deficiency generates abnormal neurotransmission. Most DMD patients show abnormalities in retinal electrophysiology (reduced b-wave in electroretinography), indicating disturbed neurotransmission (Cibis et al., 1993; Fitzgerald et al., 1994) , and a high proportion also show defects in colour vision (Costa et al., 2007) . Thus, ultimately, appropriate methods will need to be developed to target the delivery of antisense oligonucleotides to all DMD-affected tissues including brain and retina in order to correct fully all elements of the DMD phenotype.
Multi-exon skipping in the dystrophin gene A significant limitation of the current splice-modulation methods for DMD is while antisense oligonucleotide compounds are not 'personalized' as such, each antisense oligonucleotide is developed for skipping of a specific exon (e.g. exon 51) and therefore for treating a specific sub-set of mutations and DMD patients. As a result, several antisense oligonucleotides will need to be developed and evaluated in clinical studies in order to treat a sizeable proportion of all patients with DMD-estimates suggest that the top 10 antisense oligonucleotides could treat in the order of 40% of all patients (Aartsma-Rus et al., 2009a) . Thus, regulatory agencies may need to re-evaluate their approach to the development and testing of personalized genetic medicines, such as antisense oligonucleotides for DMD, in order to permit the fast-tracking of 'classes' of antisense oligonucleotide compounds (rather than specific antisense oligonucleotide sequences) for clinical approval. However, an alternative scientific approach would be to reduce the overall number of antisense oligonucleotides required by engineering them to skip multiple, non-adjacent DMD exons, thereby providing a more 'universal' antisense oligonucleotide for DMD treatment. Studies to date that have investigated multi-exon skipping (Aartsma-Rus et al. However such studies illustrate the challenge of modulating alternative splicing within a complex pre-mRNA transcript such as the DMD pre-mRNA. The DMD transcript comprises 79 exons stretching over 2.2 Mb on the X chromosome, transcriptional processing of which results in the splicing of upstream exons (e.g. exon 43) hours before downstream exons (e.g. exon 53) are processed (Tennyson et al., 1995) . It will therefore be important to acquire a more detailed knowledge of alternative splicing in the DMD gene and how this is regulated, particularly in the region from exons 40-55 where a high proportion of DMD deletions are clustered. Such fundamental splicing knowledge is now starting to be obtained. For example the likelihood of a given exon being included in the mature mRNA transcript is known to be dependent on the rate of gene transcription, and the relative size of neighbouring introns and exons (Matlin et al., 2005) . What will be required in the future will be the development of methods based on single antisense oligonucleotides that are able to perturb alternative splice regulation simultaneously at multiple loci within a given pre-mRNA transcript. This will not only open the door to generic 'universal' splice-modulating antisense oligonucleotides for all patients with DMD but will probably provide tools that allow more intelligent modulation of gene activity in general.
Antisense oligonucleotide splice-correction for other neuromuscular disorders
The clinical progress in evaluating antisense oligonucleotide splice-modulation therapy for DMD and the understanding of how to deliver and target such antisense oligonucleotides systemically to affected tissues opens the possibility of this method being exploited more widely to treat the range of neuromuscular diseases related to splicing. A number of neuromuscular diseases with a link to defects alternative splicing are shown in Table 1 . After DMD, perhaps those that appear the most tractable targets for antisense oligonucleotide therapy are SMA and myotonic dystrophy.
SMA is a group of mostly inherited disorders that cause motoneuron degeneration and constitute a leading genetic cause of infant mortality (Talbot and Davies, 2001) . Autosomal recessive SMA is the commonest form and arises due to loss-of-function mutations in the SMN1 (survival motoneuron) gene. As the nomenclature suggests, an SMN2 gene exists which encodes the same open reading frame, and which is thought to be an SMN1 paralogue that arose by evolutionary duplication. However, SMN2 incorporates a C4T single nucleotide substitution in exon 7 that, without altering the amino acid encoded, alters SMN2 pre-mRNA splicing probably via the elimination of an exonic splicing enhancer containing an alternative splicing factor/splicing factor 2 regulatory factor binding site (Cartegni and Krainer, 2003) and/or the creation of an exonic splicing silencer associated with the splicing repressor heterogeneous nuclear ribonucleoprotein A1 (Kashima and Manley, 2003) . This results in the generation of less than 10% of normal functional SMN protein from this locus (Burghes and Beattie, 2009) . As a consequence there is considerable heterogeneity in the SMA phenotype, with severe SMA occurring when levels of functional SMN protein are reduced by 80% (Lefebvre et al., 1997) . However, SMN levels can be naturally modulated by the number of genomic SMN2 copies in individual patients, thereby modifying the disease phenotype. SMN has a ubiquitous and essential function involving correct assembly of small nuclear ribonucleoprotein/spliceosomal complexes required for pre-mRNA splicing. However, SMN's neuronal-or motoneuronal-specific function is largely unknown and therefore the precise mechanism of motoneuron degeneration remains elusive. Nevertheless, recent evidence suggesting tissue-specific splicing dysregulation, perhaps due to the fact that the small nuclear ribonucleoprotein content in different tissues is sensitive to differing degrees of SMN loss (Zhang et al., 2008) , may provide new insight (Talbot and Davies, 2008; Zhang et al., 2008; Burghes and Beattie, 2009) .
A potential therapeutic approach for SMA would therefore be to increase expression of functional SMN transcripts from the intact SMN2 loci, which are largely non-functional due to exon 7 exclusion in pre-mRNA processing. The challenge to develop a splice-correction therapy for SMA would therefore involve intervention to redirect splicing of exon 7 of the SMN2 pre-mRNA to favour inclusion rather than exclusion of the exon (Fig. 3) , and therefore increase the level of functional SMN protein. This is however more challenging than conventional exon skipping Figure 3 Antisense oligonucleotide-mediation splice-correction for other neuromuscular diseases. In DMD patients with an exon 50 deletion, exon 51 can be excluded by targeting the exon 51 region, including at the exonic splicer enhancer (ESE) site, with short homologous antisense oligonucleotide sequences to restore the DMD reading-frame and produce functional dystrophin protein (A). In other neuromuscular diseases, typified by SMA, therapeutic effects will require not exon exclusion but inclusion. SMA results from SMN1 loss-of-function, however an SMA modifier gene SMN2 exists incorporating a single nucleotide modification in exon 7 that abolishes an exonic splicing enhancer leading to low level production of functional SMN protein from this locus. Strategies to enhance exon 7 inclusion within the SMN2 pre-mRNA are therefore predicted to yield enhanced functional SMN protein synthesis. An example of such an approach developed by Hua et al. (2008) is shown in B, whereby antisense oligonucleotides directed to inhibit the intronic splice silencer site (ISS) in intron 7 of the SMN2 gene have a powerful effect on pre-mRNA processing, leading to a greater probability of exon 7 inclusion within the mature mRNA transcript and resulting in the increased production of normal SMN protein (Hua et al., 2008) . Myotonic dystrophy (DM1) is caused by RNA gain-of-function due to an expanded CUG repeat in the DMPK transcript. Possible therapeutic methods are shown in C and include; antisense oligonucleotide-or siRNA-mediated knockdown of the CUG repeat RNA and inhibition of the RNA gain-of-function with antisense oligonucleotides or small molecule drugs that release sequestered MBNL1 protein and correct the dysregulated splicing phenotype.
(as described above for DMD), since instead of blocking splicing (to exclude an exon) a positive effect must be generated to suppress the signals that are present to direct natural exon exclusion. Approaches to enhance exon 7 inclusion have included screens for small molecules (Zhang et al., 2001) , trans-splicing methods (Coady et al., 2007) as well as antisense oligonucleotide-based strategies. Proof-of-principle for the use of antisense oligonucleotides was initially obtained in cell culture to block the 3 0 splice site of exon 8 (Lim and Hertel, 2001 ). These methods have been further developed using bifunctional antisense oligonucleotides that directly target exon 7 and which incorporate exonic splicing enhancer motifs to enhance exon recognition, recruit Serine/ aRginine (SR) proteins and lead to an increased probability of exon inclusion (Skordis et al., 2003) . Similarly the design of bifunctional antisense oligonucleotides covalently coupled to aRginine/ Serine (RS) peptides (i.e. a sequence corresponding to a functional domain in the SR protein itself) that activate splicing and exon 7 inclusion through the recruitment of spliceosomal components has also been successful (Cartegni and Krainer, 2003) . While such methods can yield splice-correction and exon 7 inclusion, the efficiency of this process is low, and much subsequent work has focused on attempts to improve antisense oligonucleotide efficiency and to discover more favourable SMN2 target sequences. In contrast to the use of long bifunctional antisense oligonucleotides, a recent study exploited a very short antisense oligonucleotide (an 8-mer) that was identified to target a GC-rich octamer region (CUGCCAGC) within intron 7 that partially overlaps with a known intronic splicing silencer motif. This antisense oligonucleotide gave powerful splicing redirection and exon 7 inclusion at low nanomolar concentrations in fibroblasts of patients with SMA, with high specificity and in the absence of detectable off-target effects (Singh et al., 2009) . In a distinct approach, Krainer and colleagues (Hua et al., 2007 ) undertook a wide screen using a different antisense oligonucleotide chemical backbone containing 2 0 -methoxyethyl ribose base modifications, arrayed across exon 7, and identified several novel 2 0 -methoxyethyl riboses that promoted efficient exon 7 inclusion and also, interestingly, that did not correspond to previously well-characterized regulatory motifs (Hua et al., 2007) . Further analysis revealed that some of the most effective of these antisense oligonucleotides mapped to putative intronic splicing silencer sequences within intron 7, and in particular to heterogenous ribonucleoprotein A1/A2 motifs (heterogenous ribonucleoprotein A/B family proteins that affect both 5 0 and 3 0 splice-site selection), providing a mechanistic explanation for their enhanced activity. Further high resolution antisense oligonucleotide screens in this intronic splicing silencer region yielded two new antisense oligonucleotides that showed highly effective exon 7 inclusion (up to 90%) in vitro and remarkably also in vivo (Hua et al., 2008) , principally in the liver and kidney following intravenous administration in human SMN2 transgenic mice, but with little evidence of splice correction in spinal cord. Ultimately, for a successful SMN splice-correction therapy, potent antisense oligonucleotides that promote highly effective exon 7 inclusion will need to be coupled with methods that allow antisense oligonucleotide delivery to target motoneurons within the CNS. The in vivo activity of such antisense oligonucleotides within the CNS has been recently shown via intracerebroventricular delivery (Baughan et al., 2009; Williams et al., 2009); Williams and colleagues (2009) demonstrating phenotypic improvement in SMNÁ7 mice in their study and confirming the therapeutic potential of such antisense oligonucleotides once delivered at high concentration to the appropriate CNS compartment. While systemic delivery of SMN splice-correcting antisense oligonucleotides to the CNS remains a major goal, this has yet to be convincingly demonstrated, although low efficiency SMN expression has been recently shown to be restored in parts of the CNS in a single study (Dickson et al., 2008 ). An alternative delivery approach for the correction of SMN2 pre-mRNA splicing, as discussed earlier for DMD, is the utilization of viral expression methods that incorporate U7 snRNA backbones for the targeted expression of antisense sequences (Madocsai et al., 2005; Marquis et al., 2007) . Using the U7 methodology to express bifunctional antisense sequences that promote intron 7 inclusion has now been shown to rescue the most severe SMA mouse model, when delivered by germline transgenesis (Meyer et al., 2009 ), testifying to their ability to significantly modify disease progression if delivered appropriately and at an early stage in the disease course. Therefore such U7-based methods, coupled with highly efficient viral delivery using adeno-associated virus-9 e.g. that permit delivery across the blood-brain barrier (Foust et al., 2009) , are likely to have therapeutic potential.
A second neuromuscular disease linked to aberrant splicing and that has been shown in principle to be susceptible to directed antisense correction is myotonic dystrophy, both type 1 (DM1) and type 2 (DM2) (Ranum and Cooper, 2006) . In DM1, the presence of expanded CTG repeats within the 3 0 untranslated region of the DMPK gene leads to transcription of an RNA containing an expanded CUG repeat beyond the normal range of 5-38 repeats, resulting in an RNA gain-of-function that causes neuromuscular disease and widespread dysregulation of alternative splicing leading to multi-system dysfunction. In DM2 a CCTG expansion in the zinc finger protein 9 (ZNF9) gene leads to splicing misregulation and disease. The underlying disease mechanism appears to be that the expanded RNA repeat region forms a hairpin containing C-G base pairs that sequesters and disrupts the functions of specific RNA binding proteins (Philips et al., 1998) . These include RNA binding proteins with particular affinities for CUG RNA repeats such as CUG binding protein 1 and muscleblind-like 1 family proteins (O'Rourke and Swanson, 2009), which regulate RNA processing and alternative splicing. A second component of DM1 pathogenesis appears to involve aberrant activation of protein kinase C which leads to up-regulated CUG binding protein 1 expression (Kuyumcu-Martinez et al., 2007) . Together muscleblind-like 1 and CUG binding protein 1 tightly regulate the transition between the expression of embryonic and adult splice variants that occurs in post-natal skeletal muscle, and which is consequently disrupted in DM1 leading to disease (Lin et al., 2006) . In such RNA gain-of-function disorders the CUG expanded RNA represents a viable therapeutic target, inhibition of which is likely to lead to at least partial disease modification as suggested by data from an inducible DM1 mouse model (Mahadevan et al., 2006) . As is the case with SMA, inhibitory approaches have included screens for small molecule inhibitors to block the binding of muscleblind-like 1 to the CUG expanded RNA repeat in DM1 (or the CCUG expanded repeat in DM2), as well as antisense oligonucleotide-based methods. Very recently Warf et al. (2009) undertook a limited small molecule library screen of compounds with affinity for structured nucleic acid and identified a compound pentamidine that was shown to block muscleblind-like 1 binding to the repeat expanded RNA. They obtained encouraging data both in vitro and in vivo in a DM1 mouse model expressing 250 repeats within the 3 0 untranslated region of the human skeletal -actin gene, and which led to partial reversal of the misregulated splicing phenotype, suggestive of pentamidine efficacy (Warf et al., 2009) . To what extent such compounds can reverse all pathogenic events in DM1 or are without off-target effects on other structured RNA elements remain to be established. A similar approach using antisense oligonucleotidemediated inhibition of the expanded RNA has also recently been reported ). Wheeler and colleagues utilized a 25-mer PMO antisense oligonucleotide containing multiple complementary CAG triplet repeats designed to bind the CUG repeat region of the expanded RNA with high affinity.
They were able to demonstrate inhibition of muscleblindlike 1 binding to the expanded RNA and redistribution of muscleblind-like 1 protein from nuclear RNA foci with most likely subsequent degradation of the RNA. With release of muscleblind-like 1 from the RNA foci, the defect in alternative splicing regulation was found to be at least partially corrected, resulting in restored ion channel function following intramuscular injection in HSA LR transgenic mice that show similar alternative splicing defects to those found in DM1 . In another recent related but distinct antisense oligonucleotide approach, 2 0 OMePS antisense oligonucleotides were used, not to modify splicing or to interrupt interaction with muscleblind-like 1, but to suppress the expression of the expanded DMPK RNA directly (Mulders et al., 2009 ). This CAG repeat-containing antisense oligonucleotide was found to suppress DMPK RNA expression by 90%, reduce RNA aggregation in DM1 patient cells and led to partial reversal of the RNA splicing defect. To what extent such findings are sufficiently specific to the mutant transcript and without detrimental off-target effects will need to be rigorously determined, however such approaches have clear clinical applicability and potential for correcting the disease phenotype in patients.
Conclusions and future prospects
Within the last few years the prospect of successful antisense oligonucleotide splice-modulation therapy for neuromuscular disease has moved a step closer, particularly for DMD but also for SMA and myotonic dystrophy. The data from the first clinical trials in DMD patients have proved highly encouraging, and technical advances in the development of methods for both directed exon exclusion and inclusion suggest that such antisense oligonucleotide splice-correction therapies may have broad application. Moreover, the recent preclinical work in DMD animal models using peptide enhanced antisense oligonucleotide delivery, suggests that solutions to the challenge of systemic and tissue-targeted delivery that will be required for effective treatment are close at hand. Close cooperation in future with regulatory agencies both in Europe and the USA will hopefully lead to new ways of looking at and regulating such 'personalized' therapies to permit their safe and cost-effective testing and the rapid development of this new generation of medicines that is much needed by patients.
